Calidi Biotherapeutics, Inc. (CLDI) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2022–2022
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Calidi Biotherapeutics, Inc. (CLDI) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.14 and trailing twelve-month earnings per share of $-1.85.
The current P/E is 100% below its 5-year average of 29.3x. Over the past five years, CLDI's P/E has ranged from a low of 27.1x to a high of 31.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, CLDI trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, CLDI trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CLDI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CLDI Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CLDI P/E vs Peers
Cell and Gene Therapy Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 19.3 | -Best | +1747%Best | |
| $226M | 6.3Lowest | -Best | +338% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CLDI Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Sep 30 2022 | $1182.00 | $43.68 | 27.1x | -8% |
| FY2022 Q2 | - | $1192.80 | $37.92 | 31.5x | +8% |
Average P/E for displayed period: 29.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLDI — Frequently Asked Questions
Quick answers to the most common questions about buying CLDI stock.
What is CLDI's P/E ratio?
Calidi Biotherapeutics, Inc. (CLDI) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-1.85. The 5-year average P/E is 29.3x and the historical range spans 27.1x to 31.5x.
Is CLDI stock overvalued or undervalued?
CLDI current P/E: -0.0x. 5-year average P/E: 29.3x. Percentile: 0th.
Is CLDI stock expensive?
CLDI is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 29.3x (0th percentile of historical range).
What is CLDI's historical P/E range?
Over the past 5 years, CLDI's P/E ratio has ranged from 27.1x to 31.5x, with a median of 31.5x and an average of 29.3x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2022–2022.
How does CLDI's P/E compare to the S&P 500?
CLDI current P/E: -0.0x. S&P 500 median P/E: 25.9x.
How does CLDI's valuation compare to Healthcare peers?
Calidi Biotherapeutics, Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is CLDI's PEG ratio?
CLDI PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 83.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CLDI's earnings yield?
CLDI earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.